Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Mucha, J
We review market size and projections for the GLP-1 sector (powered by the obesity/metabolic disease epidemic), and we highlight Lillys blockbuster sales, R&D moves, partnerships, and how it stacks up against competitors like Novo Nordisk
The New England Journal of Medicine, 369 (20), 19351944
Therefore, multi-targeting or unimolecular peptides possessing combinatorial agonism at GIPR, GLP-1R and GCGR have been extensively explored and more than a dozen peptides including two GIPR/GLP-1R dual agonists, ten GLP-1R/GCGR dual agonists and five GIPR/GLP-1R/GCGR triagonists have entered into clinical development (Supplementary Fig
US$ 21.75
.jpg)
US$ 23.66
US$ 25.54
